What is Axbio?
Founded in 2016 and headquartered in Silicon Valley with R&D centers in Silicon Valley and Shenzhen, Axbio is a startup deeply entrenched in precision medicine and the healthcare industry. The company specializes in the research and development of core technologies for next-generation gene sequencing and precision diagnostic equipment, offering comprehensive solutions to the sector. Axbio's leadership comprises seasoned entrepreneurs from Silicon Valley, global corporate executives, and expert scientists, bringing extensive experience in high-tech company creation, management, and successful exits. Their multidisciplinary team possesses expertise across integrated circuits, semiconductors, biochemistry, organic chemistry, surface physics, microfluidics, physical chemistry, big data, and artificial intelligence, enabling the development of sophisticated molecular diagnostics and gene sequencing products.
How much funding has Axbio raised?
Axbio has raised a total of $100.3M across 2 funding rounds:
Debt
$350K
Series B
$100M
Debt (2020): $350K with participation from PPP
Series B (2022): $100M led by Yunfeng Capital and Alibaba Group
Key Investors in Axbio
Yunfeng Capital
Yunfeng Capital is a prominent investment firm focused on nurturing young entrepreneurs and building great companies, with a particular interest in technology and healthcare sectors. They provide not only capital but also strategic guidance to their portfolio companies.
Alibaba Group
Alibaba Group is a global e-commerce, retail, Internet, and technology conglomerate. Their investment in Axbio suggests a strategic interest in the intersection of technology and healthcare, potentially leveraging Axbio's diagnostic capabilities within their broader digital health initiatives.
What's next for Axbio?
The recent major strategic investment, contextualized by the company's enterprise-level funding history, suggests Axbio is poised for significant scaling and market expansion. This backing will likely fuel further advancements in their gene sequencing and precision diagnostic technologies, potentially enabling broader clinical adoption and strategic partnerships within the global healthcare ecosystem. The company's focus on cutting-edge R&D and its experienced leadership team position it for continued innovation and growth in the rapidly evolving precision medicine landscape.
See full Axbio company page
